Tumor necrosis factor-a (TNF) is a multifunctional protein hormone that contributes to host defense and perinatal immunologic development. Dysregulated TNF production, however, occurs during the pathogenesis of autoimmune diseases and may be inherent to their development. In animal models of autoimmunity, dysregulated TNF synthesis has resulted from mutations in TNF gene regulatory sequences, specifically those sequences involved in translational control of TNF gene expression. In this study, we have determined whether mutations in the TNF translational control sequences are present in pediatric patients with type I diabetes mellitus and connective tissue diseases. Blood samples were collected from 48 patients with connective tissue diseases, 32 patients with diabetes, and 29 controls. A 250-bp fragment of the translational control sequences present in the T NF is a pluripotent cytokine, encoded in the MH C, which mediates inflammatory responses (1) (2) (3) (4) (5) . Appropriately regulated, TNF biosynthesis is critically important to host defense (6) and immune onto geny (7, 8) . Howe ver, dysr egulated TNF production may lead to the dev elopm ent of autoimmunity, as evidenced by recent data from anima l mode ls and patients. In type I diabetes mellitus, TNF potentiates IL-1-mediated islet cell toxicity in vitro and enhances interferon-induced HLA class II gene expression on islet cells (9, 10) . Furtherm ore, overexpression of TNF in the pancreatic islets of tran sgenic mic e results in chronic lymphocytic insulitis (11 , 12) . Dysregulated TNF prod uction has also been imp licat ed in the pathogenesis of RA. Elevated TNF level s are present in the joint fluid of RA patients (13) and may promote carti lage breakdown by chondrocytes and bone resorpt ion by osteo clasts (14, 15) .
Given these associations, severa l investigators have speculated that mutations within the TNF gene might account for the MHC-linked components of diabetes, RA, and other auto immun e diseas es (16, 17) . Inde ed, interindividual variations in TNF secretory capacity have recently been correlated with HLA haplotypes, restriction fragm ent length polymorphisms, TNF 3'-untranslated region was amplified by the polymerase chain reaction, sequenced, and analyzed relative to the published TNF sequence. In this study, all patients and controls exhibited the normal sequence, with no insertions or deletions in the translational control motifs. We conclude that polymorphisms in the TNF 3' -untranslated region occur infrequently, if at all, in patients with diseases examined here. (Pediatr Res 37: 165-168, 1995) Abbreviations TNF, tumor necrosis factor-a 3' -UTR, 3' untranslated region RA, rheumatoid arthritis peR, polymerase chain reaction and TNF microsatellites (18) (19) (20) . Pres um ably, these genetic m arkers reflect the existence of TNF alleles with mutations in the regu latory regi ons of the TNF gene. Among these regu latory regions is the TNF 3'-UTR, which pow erfully regul ates TNF expression at the level of translation (3, 21, 22) . Evolutionaril y con served motifs ("TIATITAT" seq uences) in the TNF 3 ' -UTR were shown to have two functions : to shorten the TNF mRNA half-life (23) and to suppress translation of TNF mRNA during normal conditions (24) . When Keffer et at. (25) repl aced these tran slation al regulatory sequences with irrelevant sequences from the 3' -UTR of the {3-globin gene, the resulting transgenic mic e displ ayed aberrant TNF production and developed chronic inflammator y pol yarthritis. Recentl y, inserti onal mutations were fo und in the TNF 3 ' -UTR "TIATI-TAT" sequences of New Zealand White mice, which are known to bear an MH C-linked gene implicated in the development of murine systemic lupus erythema tosus (26) . Th ese data further sugges t that pol ymorphisms in the TNF tran slational control region may be associated with the development of autoimmunity in certain controlled systems.
Inasmuch as the TNF 3 ' -UTR is an im port ant regulator of TNF biosynthesis and is associ ated with autoi mm une conditions in animal mo dels, we und ertook our study to determine whether mutations in the TNF 3' -UTR w ere present in pediatric patients wi th autoimmunity. Based on animal models and known associ ations of human TNF polymorphisms with autoimmun e diseases, we chose type I diabetes mellitu s and juvenile arthritis as the primary diseases for study. 29 A total of 109 patients and volunteers were enrolled into the study, 80 of whom were diagnosed with conne ctive tissue diseases or type I diabetes. Th e clinic al diagnoses suppli ed by the patients ' attending physician s are listed in Table 1 . A 250-bp segment of the TNF 3'UTR containing the known TNF translational regulatory sequences (Fig. 1) Genomic DNA purification. A 500-pL blood sample was collected in Ca-EDTA specimen tubes from each patient enrolled in the study. Cellul ar elements were pelleted by centrifugation for 10 s at 10 000 X g; pellets were washed twice for 10 s in 500 J-LL of a soluti on consisting of 10 mM Tris, 1 mM EDTA , pH 8. Pellets were then resuspended in 100 J-LL of a solution containing 0.5% Tween 20, 50 mM KCI, 10 mM Tris, pH 8.3, and 2.5 mM MgCI 2 . Fifteen J-Lg of Proteinase K (Sigma Chemical Co., St. Louis, MO) were then added and incubated for 1 h at 60°C. The samples were then heated to 100°C for 10 min; a lO-J-LL aliquot of this solut ion was next subjec ted to PCR amplification.
peR. A 250-bp segm ent of the TNF 3' UTR was amplified using Vent polymerase (New England Biolabs, Boston , MA) and primers with the sequences 5'-CCCGAGCTCTTAGGC-CTTCCTCTCTCCAGA containing an upstream Sad site and 5'-CCCGGATC CGTTCAGCTCCGTTTTCACGGA containing a downstream BamHI site. The designed restriction sites of the oligonucl eotide prim ers allowed for ligation of amplified fragments into the vector pGEM 3Z (Promega Biotec, Madison, WI) for sequencing. Clones containing the 250-bp insert were then sequenced by the Sanger dideoxynucleotide chain termination method using M13 univer sal primers that match vector sequence flanking the fragment cloning site.
Clinical and experimental evidence suggest that dysregulated TNF biosynthesis is import ant in the path ogenesis of certain autoimmune conditions. In patients with RA, TNF levels are elevated in both the syste mic circul ation and the synovial fluid obtained from diseased joints (13, 27) . In situ hybridi zation and immunochemistry have localized TNFprodu cing cells to the cartilage-pannus junction, which is the leading edge of tissue destruction in affected joints (28, 29) . In experimental models, instillat ion of TNF and IL-1 into the synovial joint space causes leukocyte infiltration, prostaglandin secr etion, cartilage destruction, and bone resorption (30) . The se and other data have led to clinical trials of MAb directed against TNF in patients with autoimmun e arthritis; a recent open label phase IIII trial demonstrated signi ficant therapyassoc iated improvements in Ritchie articular index, swollen joint count, and biochemic al parameters of inflammation (31) .
Data from animal models and from humans also implicate dysregulated TN F biosynthesis and secretion in the pathogenesis of type I diabetes mellitus, although the precise mechanisms of TNF action are debatable. TNF may be produced by pancr eatic islet cells (32) or by lymphocytes that infiltrate the islets during the course of acute insulitis (33) . TNF may be directly toxic to islet cells or may be indirectl y injurious by enhancing IL-1 toxicity, up-regulating MHC class II gene expression, or inducing islet secretion of IL-6 (9, 10, (34) (35) (36) (37) (38) . In contrast to local proinflammatory properties of TNF secreted within the islets, it is well established that nonobese diabetic mice profoundl y underproduce TNF in response to provocative stimuli (26) ; in these animals and in the diabetes-pron e BB rat, long-term admini stration of TNF significantly reduces the severit y and incidence of diabetes (39, 40) .
Theoretically, the association between abnorm al patterns of TNF production and the development of autoimmunity may be PCR and subcloned; a minimum of four clones from each PCR were sequenced. Two additional PCR amplifications followed by subcloning and sequencing were done on samples that initially appeared to display mutations to elimin ate PCR or sequencing artifact. In this study, all patients and controls exhibit ed the norm al, wild-type sequence, with no evident deletions or insertions in the "TTA1TIAT" sequences or other TA-rich motifs. 32 If primary dysregulation of TNF production were causative of autoimmunit y, then traditional MHC-disease associations may reflect mutations within the TNF locus itself. Consistent with this hypothesis are provocative data recently reported by several investigators. TNF secretory capacity in humans was shown to correlate with several genetic markers including HLA haplotype s (41), TNF-j3NeoI restriction fragment length polymorphisms (42) , and TNF microsatellites (18) . Diabetesassociated haplotypes carry an allele that correlates with high TNF secretory capacity, with DR3 + and DR4+ patients being the highest TNF responders. Furthermore, DR3/4 heterozygou s diabetic patients have a significant increase in the frequency of TNFa2 microsatellite compared with DR3/4 individuals without diabetes who possess the TNFa6 microsatellite allele (18) .
The search for mutations in the TNF gene that might account for these allelic associations is currently under way. Wilson et al. (43) reported an allelic polymorphism at position -308 of the TNF promoter, which is associated with the autoimmuneprone human HLA haplotype A1,B8,DR3. However, no functional significance to this polymorphism has yet been established (44) . In addition , a polymorphic variation in the putative "Y box " of the TNF promoter has been described by D'Alfonso and Richiardi (45) . Recently, attention has also been directed to the TNF 3' -UTR and in particular the octameric "TTATTTAT" motifs therein, which govern TNF mRNA stability (23) and translational efficiency (3). Substitution of the TNF 3'-UTR by a j3-globin 3'-UTR resulted in transgenic mice that displayed inflammatory polyarthriti s; this arthritis was eliminated by administration of MAb directed at TNF from the time of the animal' s birth (25) . Most recently, Jacob and Tashman (26) and Beutler and Brown (46) have simultane ously reported insertional mutations in the "TTATT-TAT" sequences of New Zealand White mice, which are known to carry an MHC-linked gene implicated in the development of murine lupus. In addition , Jacob (16) demonstrated that the presence of this insertion in New Zealand White mice and three other murine strains closely correlated with a decreased TNF secretory capacity to provoc ative stimulation.
Our study is the first to specifically examine the 3'-UTR in humans with autoimmunity . We initially chose patients with diabetes and juvenile arthritis because of the widespread evidence suggesting TNF 's pathogenic importance in these conditions. Sequence analysis of the TNF 3' -UTR in 109 patients and controls indicated that polymorphisms in this region occur infrequentl y, if at all, in the patient populations we examined. It remains possible that such mutations may occur in other autoimmune diseases not examined in this report, or in a very small percentage of patients with diabetes and arthritis. It is also possible that such mutations do not exist at all in humans. Additional studies should be done to distinguish among these possibilities.
